Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets. (1st February 2023)

• Record Type: Journal Article
• Authors: Morse, Joshua W.; Rios, Margarita; Ye, John; Rios, Adan; Zhang, Cheng Cheng; Daver, Naval G.; DiNardo, Courtney D.; Zhang, Ningyan; An, Zhiqiang
• Is Part Of: Expert opinion on investigational drugs. Volume 32:Number 2(2023)
• Page Start: 107
• Page End: 125
• Publication Date: 2023-02-01
• Subjects: Acute myeloid leukemia -- antibody -- antibody-drug conjugate -- bispecific antibody -- CD33 -- CD47 -- fusion protein -- immunotherapy -- LILRB4 -- targeted therapy; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2023.2179482
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction: Acute myeloid leukemia (AML) is the most common and deadly type of leukemia affecting adults. It is typically managed with rounds of non-targeted chemotherapy followed by hematopoietic stem cell transplants, but this is only possible in patients who can tolerate these harsh treatments and many are elderly and frail. With the identification of novel tumor-specific cell surface receptors, there is great conviction that targeted antibody therapies will soon become available for these patients. Areas covered: In this review, we describe the current landscape of known target receptors for monospecific and bispecific antibody-based therapeutics for AML. Here, we characterize each of the receptors and targeted antibody-based therapeutics in development, illustrating the rational design behind each therapeutic compound. We then discuss the bispecific antibodies in development and how they improve immune surveillance of AML. For each therapeutic, we also summarize the available pre-clinical and clinical data, including data from discontinued trials. Expert opinion: One antibody-based therapeutic has already been approved for AML treatment, the CD33-targeting antibody-drug conjugate, gemtuzumab ozogamicin. Many more are currently in pre-clinical and clinical studies. These antibody-based therapeutics can perform tumor-specific, elaborate cytotoxic functions and there is growing confidence they will soon lead to personalized, safe AML treatment options that induce durable remissions.